Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yaqian Han

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Cancer Science|November 16, 2022
LPLUNC1 reduces glycolysis in nasopharyngeal carcinoma cells through the PHB1-p53/c-Myc axisLinda Oyang, Lei Ouyang, Lixia Yang, et al.
Frontiers in Oncology|February 9, 2023
The role of tripartite motif-containing 28 in cancer progression and its therapeutic potentialsYiqing Yang, Shiming Tan, Yaqian Han, et al.
Journal of Advanced Research|March 10, 2025
SRSF9 mediates oncogenic RNA splicing of SLC37A4 via liquid-liquid phase separation to promote oral cancer progressionQiu Peng, Lujuan Wang, Ying Long, et al.
Genes & Diseases|June 30, 2025
Fusion genes in cancers: Biogenesis, functions, and therapeutic implicationsHaiqiong Tang, Qiu Peng, Linda Oyang, et al.
Oncogene|March 20, 2019
LPLUNC1 stabilises PHB1 by counteracting TRIM21-mediated ubiquitination to inhibit NF-κB activity in nasopharyngeal carcinomaHeran Wang, Yujuan Zhou, Linda Oyang, et al.
Molecular Therapy Oncolytics|March 14, 2022
Exosomal miR-205-5p enhances angiogenesis and nasopharyngeal carcinoma metastasis by targeting <i>desmocollin-2</i>Wenjuan Yang, Shiming Tan, Lixia Yang, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 10, 2023
Exosomal cargos-mediated metabolic reprogramming in tumor microenvironmentShiming Tan, Yiqing Yang, Wenjuan Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2025
Anti-LAG-3 Antibody LBL-007 Plus Tislelizumab and Chemotherapy as First-Line Therapy for Advanced Nasopharyngeal Carcinoma: A Multicenter Phase 2 TrialDongchen Sun, Gang Chen, Yu Chen, et al.
Frontiers in Veterinary Science|April 4, 2022
Accuracy of Genomic Selection for Important Economic Traits of Cashmere and Meat Goats Assessed by Simulation StudyXiaochun Yan, Tao Zhang, Lichun Liu, et al.
The Lancet. Oncology|June 1, 2024
BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 studyYuxiang Ma, Yan Huang, Yuanyuan Zhao, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Cancer Science|November 16, 2022
LPLUNC1 reduces glycolysis in nasopharyngeal carcinoma cells through the PHB1-p53/c-Myc axisLinda Oyang, Lei Ouyang, Lixia Yang, et al.
Frontiers in Oncology|February 9, 2023
The role of tripartite motif-containing 28 in cancer progression and its therapeutic potentialsYiqing Yang, Shiming Tan, Yaqian Han, et al.
Journal of Advanced Research|March 10, 2025
SRSF9 mediates oncogenic RNA splicing of SLC37A4 via liquid-liquid phase separation to promote oral cancer progressionQiu Peng, Lujuan Wang, Ying Long, et al.
Genes & Diseases|June 30, 2025
Fusion genes in cancers: Biogenesis, functions, and therapeutic implicationsHaiqiong Tang, Qiu Peng, Linda Oyang, et al.
Oncogene|March 20, 2019
LPLUNC1 stabilises PHB1 by counteracting TRIM21-mediated ubiquitination to inhibit NF-κB activity in nasopharyngeal carcinomaHeran Wang, Yujuan Zhou, Linda Oyang, et al.
Molecular Therapy Oncolytics|March 14, 2022
Exosomal miR-205-5p enhances angiogenesis and nasopharyngeal carcinoma metastasis by targeting <i>desmocollin-2</i>Wenjuan Yang, Shiming Tan, Lixia Yang, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 10, 2023
Exosomal cargos-mediated metabolic reprogramming in tumor microenvironmentShiming Tan, Yiqing Yang, Wenjuan Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2025
Anti-LAG-3 Antibody LBL-007 Plus Tislelizumab and Chemotherapy as First-Line Therapy for Advanced Nasopharyngeal Carcinoma: A Multicenter Phase 2 TrialDongchen Sun, Gang Chen, Yu Chen, et al.
Frontiers in Veterinary Science|April 4, 2022
Accuracy of Genomic Selection for Important Economic Traits of Cashmere and Meat Goats Assessed by Simulation StudyXiaochun Yan, Tao Zhang, Lichun Liu, et al.
The Lancet. Oncology|June 1, 2024
BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 studyYuxiang Ma, Yan Huang, Yuanyuan Zhao, et al.
Pageof 8